EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study

Sara Al Lawati, Raya Al Maskari iD, Juhaina Al Maqbali, Aly Abdelrahman

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70458 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Sara Al Lawati und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Oman. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study aimed to identify the association of dapagliflozin treatment with renal function and safety profile in patients with Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) in comparison with patients not treated with dapagliflozin.

Methods

This was a single‐centre, retrospective study including adult patients (≥18 years) with T2DM and CKD treated between January 2020 and December 2024. Patients with missing medical records, patients treated for heart failure and patients with estimated glomerular filtration rate (eGFR) < 25 mL/min were excluded.

Results

A total of 200 patients were included, of these 49.5% were male. The median follow‐up was 2.1 years. Mean eGFR showed significantly lower deterioration in the dapagliflozin group compared to the non‐dapagliflozin group (−2.1 ± 7.0 vs . ‐8.6 ± 10.9 mL/min/1.73 m 2 ; p < 0.01). Multivariate analysis revealed that dapagliflozin was an independent predictor of renal protection (OR = 4.279, 95% CI: 1.002–7.56; p = 0.011). Dapagliflozin was associated with less hospital admissions (30% vs . 44%; p = 0.04) with no differences in the adverse effects profiles between the two groups.

Conclusion

The use of dapagliflozin was associated with significant renal protection and lower hospitalizations without compromising patient safety. These findings support the beneficial role of dapagliflozin in preserving renal function in this high‐risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesDiabetes Mellitus, Type 2Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsDiabetic NephropathiesHumansRetrospective StudiesMaleGlomerular Filtration RateMiddle AgedFemaleAgedHospitalization

Stichwörter der Autor:innen

chronic kidney diseasedapagliflozinestimated glomerular filtration ratetype 2 diabetes mellitus

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Oman.

ORCID-Profile: Raya Al Maskari

Zitieren

APA

Al Lawati, S., Al Maskari, R., Al Maqbali, J., & Abdelrahman, A. (2026). Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70458

Vancouver

Al Lawati S, Al Maskari R, Al Maqbali J, Abdelrahman A. Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70458

BibTeX
@article{AlLawati2026,
  author = {Al Lawati, Sara and Al Maskari, Raya and Al Maqbali, Juhaina and Abdelrahman, Aly},
  title = {Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70458}
}
Kostenlos starten →